Griffithsin Nanocarrier Delivery for Respiratory Viruses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for respiratory virus infections, such as COVID-19, are inadequate in preventing severe courses and long-term symptoms, with existing vaccines not meeting global demand, highlighting the need for effective prophylactic and therapeutic options with proven safety profiles.
Innovation Solution
The use of nanoencapsulated Griffithsin (GRFT) delivered via targeted nanocarriers specifically binding to C-type lectin receptor (CLR)-positive cells, combined with non-encapsulated GRFT, to effectively target and treat respiratory viruses like SARS-COV-2 and influenza.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are developed and deployed to prevent respiratory virus infections, then immunity and prevention capability are improved, but production capacity and global availability remain insufficient to meet worldwide demand
Solution Approach 1:
The patent introduces nanocarrier particles as intermediary delivery vehicles that transport Griffithsin to target cells. These nanocarriers mediate the delivery of the antiviral agent, enabling controlled release and enhanced cellular uptake, thereby improving the effectiveness and availability of the treatment option.
2Reliability
If high doses of GRFT are administered to achieve therapeutic effect, then antiviral efficacy is improved, but safety profile and tolerability worsen due to potential side effects
Solution Approach 1:
The nanocarriers are functionalized with C-type lectin receptor-targeting ligands that enable selective binding to and uptake by infected cells. This localized delivery ensures that GRFT is concentrated at the site of infection rather than distributed systemically, improving antiviral efficacy while minimizing exposure of healthy tissues to the drug and reducing potential side effects.
Solution Approach 2:
The nanocarrier acts as an intermediary that protects GRFT from premature degradation and controls its release kinetics. This mediated delivery system allows for sustained release of GRFT at the target site, maintaining therapeutic concentrations longer while reducing the need for high cumulative doses.
3Productivity
If non-targeted nanocarrier delivery is used for GRFT, then delivery efficiency is partially improved, but targeting precision worsens resulting in off-target effects and reduced therapeutic index
Solution Approach 1:
The nanocarrier surface is modified with specific ligands that recognize and bind to C-type lectin receptors overexpressed on virus-infected cells. This creates local specificity at the target site while maintaining the overall nanocarrier delivery system's efficiency. The targeted ligands ensure that GRFT is preferentially delivered to infected cells rather than distributed non-specifically throughout the body.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the delivery and efficacy of GRFT, reducing viral burden, preventing progression to chronic infection, and minimizing symptoms by targeting both intracellular and extracellular viral reservoirs with lower doses, thus offering a superior safety and efficacy profile compared to unencapsulated GRFT.
Implementation Method 1
targeted nanocarrier-mediated delivery of GRFT to CLR-positive cells or CRD-positive cells infected with, or susceptible to infection with, a respiratory virus
Implementation Method 2
Griffithsin (GRFT) is a carbohydrate-binding protein made of 121 amino acids... It has three identical carbohydrate-binding sites
Data Source
AI summary
The present invention relates to Griffithsin (GRFT) for use in a method of preventing or treating infections with respiratory viruses, wherein the GRFT is encapsulated. A preferred embodiment is a combination of targeted nanocarrier-mediated delivery of GRFT and non-encapsulated GRFT to GLR-positive cells infected with, or susceptible to infection with, a respiratory virus.